Haleon (LSE:HLN) Insider Ownership : 0.01 % (As of Dec. 12, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Haleon's insider ownership is 0.01%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Haleon's Institutional Ownership is 43.91%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Haleon's Float Percentage Of Total Shares Outstanding is 0.00%.

Haleon Insider Ownership Historical Data

The historical data trend for Haleon's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Insider Ownership Chart

Haleon Historical Data

The historical data trend for Haleon can be seen below:

	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Insider Ownership	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

Haleon Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Haleon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (LSE:HLN) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

HLNCF:USA HLN:USA HLNl:UK H6D0:Germany

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.